Neurocrine Biosciences develops and commercializes medicines for neurological and endocrine diseases. Its work centers on discovering and developing treatments, with INGREZZA (valbenazine) approved to treat adults with tardive dyskinesia and a pipeline of other drug candidates in various clinical stages. The company earns revenue from sales of approved medicines and from milestones and royalties from collaborations with partners. By focusing on both neurological and endocrine conditions, Neurocrine targets patients and healthcare professionals seeking therapies for conditions such as tardive dyskinesia, Parkinson's disease, and endometriosis. Its main goal is to bring therapies to market through development and commercialization, supported by ongoing research across its clinical programs to address unmet medical needs in these areas.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1992
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Parental Leave
Health Insurance
Dental Insurance
Vision Insurance
Paid Holidays
Neurocrine Biosciences welcomes back Eiry Roberts as Chief Medical Officer. September 29, 2026 Content Marketing Editor Why This Matters: See our coverage of other industry executive team appointments and promotions here. Neurocrine Biosciences named Eiry Roberts, MD, Chief Medical Officer, returning Roberts to a post she held from 2018 to 2025. Roberts had remained linked with Neurocrine in the intervening time as a Strategic Advisor. Resulting from this appointment, Sanjay Keswani, MD, is departing Neurocrine by mutual agreement. Chief Medical Officer's resume. During her previous tenure, Roberts led indication expansion efforts for Ingrezza (valbenazine). She also spearheaded the development program that led to U.S. FDA approval of Crenessity (crinecerfont). Before joining Neurocrine, Roberts spent 26 years at Eli Lilly and Company, most notably as Vice President, Research and Development. Roberts served on the Board of Directors of Amicus Therapeutics prior to its April 2026 acquisition by BioMarin Pharmaceutical. Currently, she serves on the Board of Directors of Bausch Health Companies. Her new appointment as CMO at Neurocrine takes effect immediately. New meets familiar at Neurocrine. "I'm honored to assume the Chief Medical Officer role again and contribute to our mission of relieving suffering," Roberts said. "Having remained closely connected to the company as a Strategic Advisor, I am excited about the opportunities ahead. I look forward to building on the teams' progress, advancing the portfolio, and ultimately delivering meaningful benefits for patients." "We're pleased to welcome Eiry back to the Chief Medical Officer role," Neurocrine President and CEO Kyle Gano, PhD, said. "Her deep knowledge of Neurocrine, our pipeline, and our clinical development programs provides strong continuity... Eiry's experience with our portfolio positions her well to lead our clinical development efforts. I look forward to working closely with her once again." Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Neurocrine Biosciences has reappointed Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr Roberts previously held the CMO position from 2018 to 2025 and has since served as a strategic adviser to the company. During her earlier tenure, Dr Roberts led indication-expansion efforts for INGREZZA and the crinecerfont development programme that resulted in FDA approval of CRENESSITY. Before joining Neurocrine in 2018, she spent 26 years at Eli Lilly and Company in senior research and development roles. By mutual agreement, Sanjay Keswani, M.D., will depart the company. CEO Kyle W. Gano noted that Dr Roberts' knowledge of Neurocrine's pipeline positions her well to lead clinical development efforts as the company advances multiple late-stage programmes.
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Neurocrine Biosciences announces initiation of Phase 1 clinical study evaluating NBIP-'1968, a glp-1/gip/glucagon receptor triple agonist. Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity. "Obesity is a complex chronic disease driven by multiple biological pathways, underscoring the need for additional treatment options," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "NBIP-'1968 is designed to engage three complementary metabolic mechanisms, reflecting our commitment to exploring multiple scientific approaches to obesity." The Phase 1 study initially will evaluate the safety and tolerability of single ascending doses of NBIP-'1968 in adult participants across a range of body mass index categories, including overweight and obese. Innovations in treatment by Neurocrine bioscience. NBIP-'1968 is an internally discovered, investigational long-acting triple agonist designed for once-weekly subcutaneous administration. It targets the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon to influence metabolic pathways involved in appetite regulation, energy balance and glycemic control. NBIP-'1968 was designed with balanced glucagon receptor activity to optimize the potential metabolic benefits of glucagon receptor activation while supporting tolerability. Neurocrine is developing NBIP-'1968 as part of a broader obesity portfolio that includes NBIP-'2118, an investigational corticotropin-releasing factor type 2 receptor agonist currently in Phase 1 development. NBIP-'1968 is intended for use in a fixed-dose combination with NBIP-'2118. The company's obesity research also includes earlier-stage programs designed to explore complementary mechanisms and extended dosing intervals. "Advancing NBIP-'1968 into the clinic marks another important step in building our obesity portfolio," said Jude Onyia, Ph.D., Chief Scientific Officer, Neurocrine Biosciences. "Our strategy is to explore complementary and differentiated mechanisms that may improve weight loss, preserve lean mass and ultimately address the diverse needs of people living with obesity." About Obesity Obesity is a chronic disease characterized by excess body fat and is associated with serious health conditions, including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis/fatty liver disease, certain cancers and osteoarthritis. It is driven by complex biological, environmental, and genetic factors - not simply lifestyle or willpower. Obesity has reached epidemic levels worldwide, affecting a significant proportion of adults and placing a substantial burden on public health systems. Despite recent advances in treatment, there remains a need for additional therapies that support safe, effective and sustainable long-term weight management. Current therapies can have challenges with respect to gastrointestinal tolerability, dose titration, and muscle loss. More news. August 7, 2026 August 6, 2026
Neurocrine Biosciences reported revenue of $959 million for the quarter ended June 2026, marking a 39.5% year-on-year increase. The figure surpassed the consensus estimate of $901.54 million by 6.37%. Earnings per share came in at $2.85, up from $1.06 a year earlier and beating the consensus estimate of $2.26 by 26.11%. Product sales reached $954.3 million, exceeding analyst estimates of $881.08 million. INGREZZA sales totalled $716 million, above the $628.59 million forecast, whilst CRENESSITY generated $184 million against an estimated $170.78 million. Collaboration revenue came in at $4.7 million, below the $6.02 million estimate and down 14.6% year-on-year. Shares rose 7.8% over the past month.